Program
olaparib
Also written as “Olaparib”, “AZD2281” and “KU-0059436 (AZD2281)(PARP inhibitor)”.
Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Prostatic Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 6 companies.
Drug pageOlaparib: every studyMany companies study it; this page follows only the 76 they lead. All 323 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 5915 open or running | phase 4since Jun 10, 2015 | Jun 27, 2007 | Apr 6, 2027phase 3 · NCT04421963 |
| Merckits history only | 125 open or running | phase 3since Mar 29, 2018 | Aug 3, 2016 | May 5, 2027phase 3 · NCT04380636 |
| Novartisits history only | 20 open or running | phase 3since Jan 25, 2021 | Jan 25, 2021 | none ahead |
| Boryung Pharmaceuticalits history only | 11 open or running | phase 1since Jul 7, 2025 | Jul 7, 2025 | none ahead |
| CSPC Pharmaceutical Groupits history only | 10 open or running | phase 1since Apr 7, 2024 | Apr 7, 2024 | none ahead |
| Daewoong Pharmaceuticalits history only | 11 open or running | phase 1since Jan 19, 2026 | Jan 19, 2026 | Mar 2027phase 1 · NCT07371104 |
Also a collaborator on its studies: Myriad Genetic Laboratories, Frontier Science & Technology Research Foundation, Hoffmann-La Roche, Myriad Genetics, Iqvia Pty, Covance, Theradex, Parexel and KuDOS Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jan 7, 2009.
- Mar 30, 2020Phase 4 study in Ovarian NeoplasmsAstraZeneca · NCT04330040 · 202 enrolled · India
- May 5, 2020Phase 3 study in Lung NeoplasmsMerck · NCT04380636 · 870 enrolled · United States, Argentina, Canada and more
- May 19, 2020Phase 3 study in Ovarian NeoplasmsAstraZeneca · NCT04421963 · 185 enrolled · United States, Belgium, Bulgaria and more
- Jul 1, 2020Phase 3 study in Colorectal NeoplasmsMerck · NCT04456699 · 335 enrolled · United States, Australia, Belgium and more
- Nov 5, 2020Phase 3 study in Small Cell Lung CarcinomaMerck · NCT04624204 · 672 enrolled · United States, Australia, Belgium and more
- Jan 25, 2021Novartis’s first study: phase 3 study in Ovarian NeoplasmsNew to NovartisNovartis · NCT04729387 · 358 enrolled · United States, Argentina, Australia and more
- Apr 20, 2021Phase 3 study in Ovarian NeoplasmsAstraZeneca · NCT04884360 · 366 enrolled · Chile, China, Colombia and more
- Dec 20, 2021Phase 3 study in Metastatic Castration-resistant Prostate CancerAstraZeneca · NCT05171816 · 110 enrolled · China
- Feb 17, 2022Phase 1 study in Ovarian NeoplasmsNovartis · NCT05258747 · 70 enrolled · India
- Jul 5, 2022Phase 2 study in Breast NeoplasmsAstraZeneca · NCT05498155 · 50 enrolled · United States, Australia, Austria and more
- Jul 11, 2022Phase 4 study in Metastatic Castration-resistant Prostate CancerAstraZeneca · NCT05457257 · 43 enrolled · China
- Apr 7, 2024CSPC Pharmaceutical Group’s first study: phase 1 study in Healthy ParticipantsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06360445 · 102 enrolled · China
- Jul 7, 2025Boryung Pharmaceutical’s first study: phase 1 study in Ovarian NeoplasmsNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT07069335 · 24 planned · South Korea
- Jan 19, 2026Daewoong Pharmaceutical’s first study: phase 1 study in NeoplasmsNew to Daewoong PharmaceuticalDaewoong Pharmaceutical · NCT07371104 · 40 planned · South Korea
Ahead
- Mar 2027Primary completion: phase 1 study in NeoplasmsDaewoong Pharmaceutical · NCT07371104
- Apr 6, 2027Primary completion: phase 3 study in Ovarian NeoplasmsAstraZeneca · NCT04421963
- May 5, 2027Primary completion: phase 3 study in Lung NeoplasmsMerck · NCT04380636
- Oct 22, 2027Primary completion: phase 2 study in Metastatic Castration-Resistant Prostate CancerMerck · NCT02861573
TargetBeta
“PARP 1, 2 and 3 inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 76 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07371104Neoplasms · South Korea | 1 | Recruiting | Daewoong Pharmaceutical | Mar 2027 | 40 |
| NCT07069335Ovarian Neoplasms · South Korea | 1 | Recruiting | Boryung Pharmaceutical | May 15, 2026 | 24 |
| NCT06360445Healthy Participants · China | 1 | Completed | CSPC Pharmaceutical Group | Aug 21, 2022 | 102 |
| NCT05457257Metastatic Castration-resistant Prostate Cancer · China | 4 | Active, not recruiting | AstraZeneca | Oct 22, 2024 | 43 |
| NCT05498155Breast Neoplasms · United States, Australia, Austria and more | 2 | Completed | AstraZeneca | Nov 20, 2024 | 50 |
| NCT05258747Ovarian Neoplasms · India | 1 | Completed | Novartis | Oct 20, 2022 | 70 |
| NCT05171816Metastatic Castration-resistant Prostate Cancer · China | 3 | Active, not recruiting | AstraZeneca | Jan 22, 2024 | 110 |
| NCT04884360Ovarian Neoplasms · Chile, China, Colombia and more | 3 | Active, not recruiting | AstraZeneca | Jul 27, 2026 | 366 |
| NCT04729387Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Novartis | Apr 21, 2023 | 358 |
| NCT04624204Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Merck | Oct 28, 2027 | 672 |
| NCT04456699Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Merck | Mar 27, 2023 | 335 |
| NCT04421963Ovarian Neoplasms · United States, Belgium, Bulgaria and more | 3 | Active, not recruiting | AstraZeneca | Apr 6, 2027 | 185 |
| NCT04380636Lung Neoplasms · United States, Argentina, Canada and more | 3 | Active, not recruiting | Merck | May 5, 2027 | 870 |
| NCT04330040Ovarian Neoplasms · India | 4 | Completed | AstraZeneca | Sep 30, 2022 | 202 |
| NCT04269200Endometrial Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jul 8, 2024 | 805 |
| NCT04239014Ovarian Neoplasms · United States, Canada, Italy and more | 2 | Withdrawn | AstraZeneca | Jan 25, 2021 | 0 |
| NCT04191135Triple Negative Breast Neoplasms · United States, Canada, Chile and more | 2 | Terminated | Merck | Dec 15, 2022 | 462 |
| NCT04236414Neoplasms · Denmark, France, Germany and more | 1 | Completed | AstraZeneca | Feb 4, 2025 | 16 |
| NCT04123366Solid Tumors · United States, Argentina, Australia and more | 2 | Completed | Merck | Jun 8, 2026 | 333 |
| NCT03976362Carcinoma · United States, Argentina, Australia and more | 3 | Completed | Merck | Sep 21, 2023 | 851 |
| NCT03976323Carcinoma · United States, Argentina, Australia and more | 3 | Completed | Merck | Feb 7, 2024 | 1,003 |
| NCT03834519Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merck | Mar 14, 2022 | 793 |
| NCT03775486Non-small Cell Lung Cancer NSCLC · United States, Belgium, Hungary and more | 2 | Active, not recruiting | AstraZeneca | Jan 11, 2021 | 401 |
| NCT03742895Advanced Solid Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Merck | Aug 12, 2025 | 329 |
| NCT03740165Ovarian Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Merck | Aug 26, 2024 | 1,367 |
| NCT03737643Ovarian Neoplasms · United States, Austria, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Mar 17, 2025 | 1,407 |
| NCT03732820Metastatic Castration-resistant Prostate Cancer · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jul 30, 2021 | 895 |
| NCT03553108Malignant Solid Tumor · Belgium | 1 | Completed | AstraZeneca | Mar 12, 2019 | 18 |
| NCT03486873Hematologic Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Aug 4, 2043 | 3,500 |
| NCT03534453Ovarian Neoplasms · China, Malaysia | 3 | Completed | AstraZeneca | Jan 27, 2025 | 225 |
| NCT03459846Urinary Bladder Neoplasms · United States, Canada, Russia and more | 2 | Active, not recruiting | AstraZeneca | Oct 15, 2020 | 154 |
| NCT03402841Ovarian Neoplasms · Austria, Belgium, Bulgaria and more | 3 | Completed | AstraZeneca | Oct 2, 2020 | 279 |
| NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more | 2 | Active, not recruiting | AstraZeneca | Sep 13, 2024 | 528 |
| NCT03286842HER2-ve Metastatic Breast Cancer · United States, Bulgaria, Canada and more | 3 | Completed | AstraZeneca | Oct 8, 2021 | 256 |
| NCT03106987Carcinoma, Ovarian Epithelial · Belgium, Canada, Denmark and more | 3 | Completed | AstraZeneca | Feb 15, 2021 | 220 |
| NCT03022409Squamous Cell Carcinoma of Head and Neck · United States, France, Taiwan | 1 | Completed | AstraZeneca | Jan 20, 2021 | 21 |
| NCT02987543Metastatic Castration-resistant Prostate Cancer · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Jun 4, 2019 | 387 |
| NCT02983799Ovarian Neoplasms · United States, Canada | 2 | Completed | AstraZeneca | Dec 3, 2020 | 272 |
| NCT02861573Metastatic Castration-Resistant Prostate Cancer | 2 | Active, not recruiting | Merck | Oct 22, 2027 | 1,200 |
| NCT02561832Breast Neoplasms · United States, Spain | 1 | Terminated | AstraZeneca | Sep 30, 2016 | 15 |
| NCT02476968BRCA or HRR+ Mutated Ovarian Cancer Patients · Bulgaria, Canada, Czechia and more | 4 | Completed | AstraZeneca | Apr 17, 2020 | 181 |
| NCT02430311Advanced Solid Tumours · China | 1 | Completed | AstraZeneca | Jul 27, 2016 | 36 |
| NCT02392676Ovarian Neoplasms · United States, Korea, Republic of, Peru and more | 3 | Withdrawn | AstraZeneca | Jun 2019 | 0 |
| NCT02282020Ovarian Neoplasms · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Oct 10, 2018 | 266 |
| NCT02184195Pancreatic Neoplasms · United States, Australia, Belgium and more | 3 | Completed | AstraZeneca | Jan 15, 2019 | 154 |
| NCT02093351Neoplasms · Belgium, Denmark, France and more | 1 | Completed | AstraZeneca | Apr 30, 2015 | 79 |
| NCT02032823Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Mar 27, 2020 | 1,837 |
| NCT02000622Breast Neoplasms · United States, Bulgaria, China and more | 3 | Completed | AstraZeneca | Dec 9, 2016 | 302 |
| NCT01972217Prostatic Neoplasms · United States, Belgium, Canada and more | 2 | Completed | AstraZeneca | Sep 22, 2017 | 158 |
| NCT01924533Stomach Neoplasms · China, Japan, Korea, Republic of and more | 3 | Completed | AstraZeneca | Apr 4, 2016 | 525 |
| NCT01921140Neoplasms · Belgium, Denmark, Netherlands and more | 1 | Completed | AstraZeneca | Apr 8, 2014 | 60 |
| NCT01874353Ovarian Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Sep 19, 2016 | 327 |
| NCT01851265Neoplasms · Belgium, Netherlands, United Kingdom | 1 | Completed | AstraZeneca | Oct 18, 2013 | 32 |
| NCT01844986Pathologic Complete Response · United States, Australia, Brazil and more | 3 | Active, not recruiting | AstraZeneca | May 17, 2018 | 450 |
| NCT01813474Neoplasms · Japan | 1 | Completed | AstraZeneca | Aug 31, 2016 | 23 |
| NCT01078662Ovarian · United States, Australia, Germany and more | 2 | Completed | AstraZeneca | Jul 31, 2012 | 298 |
| NCT01081951Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Active, not recruiting | AstraZeneca | Oct 10, 2011 | 162 |
| NCT01063517Stomach Neoplasms · Korea, Republic of | 2 | Completed | AstraZeneca | May 11, 2012 | 124 |
| NCT00912743Colorectal Neoplasms · United States | 2 | Completed | AstraZeneca | Mar 2012 | 33 |
| NCT00819221Solid Tumors · Italy, Switzerland | 1 | Terminated | AstraZeneca | Nov 30, 2011 | 44 |
How it is read
Names in the registry
- “Olaparib”, 38 entries
- “olaparib”, 10 entries
- “AZD2281”, 10 entries
- “KU-0059436 (AZD2281)(PARP inhibitor)”, 10 entries
- “Olaparib 300mg tablets”, 3 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 24 studies
- Breast Neoplasms, 7 studies
- Prostatic Neoplasms, 7 studies
- Neoplasms, 6 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.